To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-005 in Healthy Volunteers
Latest Information Update: 11 Mar 2024
At a glance
- Drugs LP 005 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man
- Sponsors LongBio Pharma
Most Recent Events
- 28 Feb 2024 New trial record